Pre-Operative Window of ET to Inform RT Decisions (POWER II)

This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated randomly assigned to one of two groups: Intervention, treated with 3 months of pre-operative endocrine therapy (pre-ET) OR Control, participants follow standard of care and proceed directly to breast cancer surgery. Both arms will be assessed for tolerance and compliance to the endocrine therapy by patient reported outcome (PRO) measures (patient surveys).

NCT Number	NCT06507618
Lead Sponsor	University of Virginia
Conditions	Breast Cancer Female
Enrollment	354 participants
Start Date	2024-07-19
Primary Completion	2029-06-30 (estimated)
Study Completion	2034-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-30